DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$3.25 USD
-0.22 (-6.34%)
Updated May 9, 2024 04:00 PM ET
After-Market: $3.24 -0.01 (-0.31%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
DMAC 3.25 -0.22(-6.34%)
Will DMAC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DMAC
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
Other News for DMAC
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
Diamedica Therapeutics Files Key SEC Report
DiaMedica Therapeutics GAAP EPS of -$0.14 beats by $0.02
DiaMedica Therapeutics reports Q1 EPS (14c), consensus (16c)